ELOX — Eloxx Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1035354 ·
Last close
$11.74
Market Cap
$40.34M
52W High
$23.40
52W Low
$8.20
ADV30
24,466
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -4,450,000 | -4,502,000 | 63,388,000 | 61,960,000 | 16,968,000 |
| Mar 2026 | 0 | — | -3,795,000 | -3,754,000 | 8,503,000 | 6,363,000 | 16,087,000 |
| Jun 2025 | 0 | — | -1,582,000 | -1,891,000 | — | — | — |
| Mar 2025 | 0 | — | -1,222,000 | -1,709,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,791,000
Investing CF
—
Financing CF
$68,427,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-11.94
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-308,836,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-11,028,000
Pretax Income TTM
$-11,856,000
Interest Exp TTM
$828,000
Analysts
4
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -6,438,000 | -5,995,000 | 5,270,000 | 17,177,000 | -11,907,000 | -6,327,000 |
| Dec 2024 | 6,359,000 | -2,468,000 | -3,143,000 | 2,976,000 | 27,311,000 | -24,335,000 | -4,715,000 |
| Dec 2023 | 0 | -17,288,000 | -17,054,000 | 1,712,000 | 24,311,000 | -22,599,000 | -14,341,000 |
| Dec 2022 | 0 | -34,419,000 | -36,065,000 | 21,123,000 | 31,783,000 | -10,660,000 | -31,845,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$63,388,000
Forward EPS
$-0.71
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ELUT | ELUTIA INC. | $37.91M | $0.85 | — |
| TVGN | Tevogen Inc. | $37.05M | $5.69 | — |
| CRBU | Caribou Biosciences, Inc. | $36.81M | $0.34 | — |
| TIL | Instil Bio, Inc. | $36.62M | $5.40 | — |
| BKHA | Black Hawk Acquisition Corp | $35.93M | $8.65 | — |
News headlines (Yahoo Finance, 1h cache)
Eloxx Pharmaceuticals Announces Publication of Phase 2a Exaluren Data in Nonsense Mutation Alport Syndrome in the Journal of Clinical Investigation
2026-11-18 21:05 · Yahoo
Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-16 12:00 · Yahoo
Eloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation Conference
2026-11-02 21:15 · Yahoo
Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD
2026-10-29 12:00 · Yahoo
Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer
2026-10-20 13:31 · Yahoo
Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors
2026-10-19 20:05 · Yahoo
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
2026-09-11 11:30 · Yahoo
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-12 10:00 · Yahoo
Eloxx Pharmaceuticals, Inc. Announces Pricing of $66.0 Million Public Offering and Uplisting to Nasdaq
2026-06-09 01:23 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.